S. Adele

发表

The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions.

K. Stepniewska, N. White, M. Brack, 2022, Wellcome Open Research.

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

P. Klenerman, A. Winston, G. Screaton, 2022, JCI insight.

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

D. Stuart, P. Klenerman, G. Screaton, 2022, Cell.

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

P. Klenerman, G. Screaton, A. Mentzer, 2022, Cell.

Potential health and economic impacts of dexamethasone treatment for patients with COVID-19

E. A. Bakare, Yu Nandar Aung, Michael G. Klein, 2021 .

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

P. Klenerman, A. Winston, G. Screaton, 2021 .

Evolution of long-term hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study

A. Mentzer, S. Faustini, A. Angyal, 2022, medRxiv.

Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2 years after allogeneic bone marrow transplant

P. Klenerman, E. Barnes, A. Amini, 2022, British journal of haematology.

Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers

P. Klenerman, E. Barnes, D. Eyre, 2022, medRxiv.

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

William T. Harvey, Scott M Elliott, Robert M. Davies, 2022, Nature Microbiology.

Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern.

P. Klenerman, E. Barnes, A. Pollard, 2021 .

Impact of restenosis after optimal directional coronary atherectomy on regional left ventricular function.

P. dos Santos, P. Coste, S. Sempé, 1997, The American journal of cardiology.

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

P. Klenerman, S. Rowland-Jones, M. Haniffa, 2021, The Lancet Microbe.

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus

P. Klenerman, A. Winston, E. Barnes, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum

P. Klenerman, G. Screaton, A. Mentzer, 2022, bioRxiv.

Two doses of SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 variants of concern than does natural infection.

P. Klenerman, A. Sigal, E. Barnes, 2021 .

Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination

P. Klenerman, Md. Zulfekar Ali, K. Jeffery, 2022, medRxiv.

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75

P. Klenerman, D. Hall, G. Screaton, 2022, Cell Reports.

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

P. Klenerman, J. Knight, P. Phalora, 2021, Nature Communications.

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

S. Madhi, D. Stuart, P. Klenerman, 2022, Cell.

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Rosalind J Wright, P. Klenerman, S. Rowland-Jones, 2021, Cell.

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

P. Klenerman, A. Winston, G. Screaton, 2021, The Lancet HIV.

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens

P. Klenerman, S. Rowland-Jones, G. Screaton, 2023, Med.

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

S. Madhi, P. Klenerman, G. Screaton, 2021, bioRxiv.

Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

William T. Harvey, Scott M Elliott, Robert M. Davies, 2022, Nature Microbiology.

COVID-19 Mortality and Progress Toward Vaccinating Older Adults — World Health Organization, Worldwide, 2020–2022

Ryan T Novak, M. V. Van Kerkhove, B. Pavlin, 2023, MMWR. Morbidity and mortality weekly report.

Potential health and economic impacts of dexamethasone treatment for patients with COVID-19

E. A. Bakare, Yu Nandar Aung, Michael G. Klein, 2020, Nature Communications.

Sustained T Cell Immunity, Protection and Boosting Using Extended Dosing Intervals of BNT162b2 mRNA Vaccine

P. Klenerman, S. Rowland-Jones, G. Screaton, 2021, SSRN Electronic Journal.

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

P. Klenerman, A. Winston, A. Goodman, 2021, SSRN Electronic Journal.

Obesity Differs from Diabetes Mellitus in Antibody and T Cell Responses Post COVID-19 Recovery

P. Klenerman, F. H. Mollah, P. Abraham, 2023, medRxiv.

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

J. Satsangi, P. Klenerman, S. Rowland-Jones, 2023, Nature Medicine.

Potential health and economic impacts of dexamethasone treatment for patients with COVID-19

E. A. Bakare, Yu Nandar Aung, Sai Thein Than Tun, 2021, Nature Communications.